EUROPEAN JOURNAL OF HEART FAILURE

Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis

Effectiveness of the European Society of Cardiology/Heart Failure Association website ‘heartfailurematters.org’ and an e‐health adjusted care pathway in patients with stable heart failure: results of the ‘e‐Vita HF’ randomized controlled trial

Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise

Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure

Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas

Improving risk prediction in heart failure using machine learning

Aetiology‐based clinical scenarios predict outcomes of transcatheter edge‐to‐edge tricuspid valve repair of functional tricuspid regurgitation

Heart failure around the world

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non‐treatable Cardiac diseasE (SCIENCE)

Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy

Association between beta‐blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score‐matched analysis from the Swedish Heart Failure Registry

Clinical and research implications of serum versus plasma potassium measurements

Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50\u2009years

Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics

Intravenous iron therapy in heart failure: a different perspective

Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study

B‐type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure

Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care

Prescription patterns of anti‐diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus

Prognostic value of baroreflex sensitivity in heart failure. A 2018 reappraisal

Physical activity tracking in correlation to conventional heart failure monitoring assessing improvements after transcatheter mitral and tricuspid valve repair

Heart failure after treatment for breast cancer

Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?

Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more

Long‐term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction

Heart failure with preserved ejection fraction in Asia: the far side of the moon?

De novo heart failure: where the journey begins

Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation

The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial

Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN‐HF registry

Lessons from follow‐up after percutaneous mitral valve repair: ‘you are judged by the company you keep’

Cardiac resynchronization therapy improves survival in selected patients with moderately impaired ejection fraction\u2009—\u2009the importance of left ventricular remodelling

The Janus‐faced Fontan circulation: unravelling its elusive pathophysiology

Cardiac rehabilitation in heart failure after the ExTraMATCH II study: who still believes?

Angiotensin–neprilysin inhibition in de novo heart failure – starting off strong

It is time for consistency in the use of biomarkers in heart failure clinical trials

Common laboratory parameters as indicators of multi‐organ dysfunction in acute heart failure

Letter on ‘Pharmacy‐based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM‐CHF randomized controlled trial’

Heart Failure Atlas, a major project of the Heart Failure Association in concert with the European Society of Cardiology

March 2019 at a glance: epidemiology and clinical trials

Two‐year outcomes of the MITRA‐FR trial: towards an integrated approach in the evaluation of patients with secondary mitral regurgitation

The price of a failing heart

Transforming the interpretation of significance in heart failure trials

The never‐ending quest for the appropriate role of ultrafiltration

Myocardial dysfunction in breast cancer survivors: ‘you can observe a lot by just watching’